U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172217) titled 'The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC' on Aug. 28.
Brief Summary: This is a single-arm study. The efficacy and safety of Disitamab Vedotin combined with Apalutamide and Toripalimab in the second-line treatment of HER2-expressing recurrent cervical cancer are evaluated based on the following indicators:
Primary evaluation indicator: Objective Response Rate (ORR)
Secondary evaluation indicators:
Efficacy-related indicators: Progression-Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (including median Overall Survival [mOS] and...